MIH
XBI icon

Meitav Investment House’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Meitav Investment House’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103M Sell
809,579
-159,840
-16% -$20M 1.13% 23
2025
Q4 		$118M Buy
969,419
+287,363
+42% +$32.9M 1.36% 20
2025
Q3 		$68.2M Buy
682,056
+281,602
+70% +$25.4M 0.9% 28
2025
Q2 		$33.2M Buy
400,454
+383,040
+2,200% +$30.6M 0.45% 51
2025
Q1 		$1.41M Hold
17,414
– – 0.03% 122
2024
Q4 		$1.57M Sell
17,414
-47,370
-73% -$4.59M 0.03% 117
2024
Q3 		$6.4M Sell
64,784
-1,810
-3% -$178K 0.11% 84
2024
Q2 		$6.17M Hold
66,594
– – 0.11% 87
2024
Q1 		$6.32M Sell
66,594
-237,210
-78% -$22M 0.12% 83
2023
Q4 		$27.1M Sell
303,804
-70,575
-19% -$5.24M 0.4% 71
2023
Q3 		$27.7M Sell
374,379
-3,499
-0.9% -$279K 0.45% 63
2023
Q2 		$31.2M Buy
377,878
+12,593
+3% +$1.05M 0.5% 61
2023
Q1 		$29.5M Buy
365,285
+289,169
+380% +$24M 0.51% 61
2022
Q4 		$6.29M Hold
76,116
– – 0.11% 137
2022
Q3 		$6M Hold
76,116
– – 0.11% 134
2022
Q2 		$5.65M Sell
76,116
-30,873
-29% -$2.32M 0.1% 134
2022
Q1 		$9.62M Sell
106,989
-3,695
-3% -$341K 0.14% 118
2021
Q4 		$12.4M Sell
110,684
-116,045
-51% -$14M 0.2% 100
2021
Q3 		$28.5M Buy
226,729
+144,890
+177% +$18.7M 0.47% 65
2021
Q2 		$11.1M Buy
81,839
+29,273
+56% +$3.85M 0.28% 83
2021
Q1 		$7.13K Buy
+52,566
New +$7.87M 0.2% 106
2020
Q4 		– Sell
-41,437
Closed -$4.62M – 472
2020
Q3 		$4.62M Buy
41,437
+25,615
+162% +$2.87M 0.23% 81
2020
Q2 		$1.77M Sell
15,822
-212,745
-93% -$21M 0.11% 103
2020
Q1 		$17.7M Buy
228,567
+225,332
+6,965% +$20M 1.32% 25
2019
Q4 		$308K Sell
3,235
-17,113
-84% -$1.48M 0.02% 319
2019
Q3 		$1.56M Buy
+20,348
New +$1.69M 0.11% 109
2019
Q2 		– Sell
-20,348
Closed -$1.84M – 489
2019
Q1 		$1.84M Buy
+20,348
New +$1.73M 0.1% 120
2018
Q4 		– Sell
-31,422
Closed -$3.01M – 453
2018
Q3 		$3.01M Buy
31,422
+300
+1% +$29.1K 0.15% 90
2018
Q2 		$10.8M Buy
+31,122
New +$2.86M 0.48% 59

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Meitav Investment House's XBI Position: Q1 2026 in Review

Meitav Investment House reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q1 2026, selling an estimated $20M and leaving 809,579 shares worth $103M. The position accounts for 1.13% of the portfolio, ranked #23.

Meitav Investment House first reported a position in XBI in Q2 2018 and has held it in 29 quarters since. The position peaked at $118M in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Meitav Investment House held 809,579 shares of State Street SPDR S&P Biotech ETF worth $103M as of Q1 2026.
  • Meitav Investment House sold 159,840 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $20M.
  • State Street SPDR S&P Biotech ETF made up 1.13% of Meitav Investment House's portfolio in Q1 2026, its #23 holding.
  • Meitav Investment House first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 29 quarters since.
  • Meitav Investment House's State Street SPDR S&P Biotech ETF position peaked at $118M in Q4 2025.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Meitav Investment House's 13F filing for Q1 2026, filed 29 Apr 2026.